Clinical Trials
24 trialsNCT03554707 2026-05-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT04105374 2026-05-07
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
Phase 2/3 Withdrawn
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00601289 2020-07-31
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT03480867 2019-08-14
PARADIGMA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 1 Withdrawn
NCT02836028 2018-09-18
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Pfizer
Phase 2 Withdrawn
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00109798 2017-09-19
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
The Methodist Hospital Research Institute
Phase NA Withdrawn
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01260103 2017-07-26
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Burzynski Research Institute
Phase 3 Withdrawn
NCT02976441 2017-02-20
Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Washington University School of Medicine
Phase EARLY_PHASE1 Withdrawn
NCT00881595 2017-02-10
SA02
University of Florida
Phase 2 Withdrawn
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT01830101 2016-03-16
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase 3 Withdrawn
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT02599090 2015-11-06
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00006263 2015-08-05
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT00601614 2014-03-10
Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Withdrawn
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00021307 2013-07-11
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Fox Chase Cancer Center
Phase 1/2 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn